What is happening with the Atlas Arteria (ASX:ALX) takeover bid?

The board of toll road operator Atlas Arteria has firmly reiterated its advice that shareholders should reject a AU$7 billion hostile takeover bid from IFM Investors.

Why did IFM Investors criticise the independent expert report for Atlas Arteria (ASX:ALX)?

IFM Investors, which is already Atlas Arteria’s largest shareholder with a dominant 35% blocking stake, publicly attacked Kroll's independent assessment as "unbalanced", "selective" and "misleading".

What is the valuation gap between Kroll's assessment and the IFM Investors bid?

There is a significant gap between what the bidder wants to pay and what the independent expert says the company is worth. Kroll restated that the true control valuation for Atlas Arteria sits between AU$5.39 and AU$6.20 per share.

How does the Atlas Arteria (ASX:ALX) share price compare to the takeover offer and valuation floor?

Atlas Arteria securities recently traded on the ASX at AU$5.02, down slightly from a previous close of AU$5.04. This market price sits comfortably above IFM's AU$4.75 bidding price, showing the market expects a higher payout, but remains below Kroll’s independent valuation floor of AU$5.39 per share.

How might this news affect the Atlas Arteria (ASX:ALX) share price in the short term?

The share price is likely to remain supported above the AU$4.75 bid floor as long as the board and independent expert stand firm. However, because IFM holds a 35% stake and can block alternative deals, trading may become highly volatile and range-bound between the bid price and Kroll's AU$5.39 floor until one side blinks.

Image for illustrative purposes only. Not a real photo.

Atlas Arteria backs expert, rejects IFM bid

Published Jun. 2 2026Last Updated Jun. 2 2026

The board of Atlas Arteria (ASX:ALX) reiterated its recommendation that shareholders reject a $7 billion hostile takeover bid from IFM Investors, following a definitive response from its independent expert.

Global advisory firm Kroll stood by its original valuation analysis, completely rejecting fierce criticism from the bidding consortium.

Atlas Arteria confirmed that Kroll remains entirely satisfied with its findings, advising independent directors that its conclusions continue to be appropriate.

The ongoing dispute heavily centres on a significant valuation gap. Kroll has restated that the true control value for the toll road operator sits between $5.39 and $6.20 per share.

The assessment is considerably higher than IFM’s current offer of $4.75 per share. Atlas Arteria securities last closed on the ASX at $5.04, sitting comfortably below Kroll's valuation floor but above the suitor's bid.

The corporate battle intensified on Monday when IFM, which already holds a dominant 35% blocking stake in the company, publicly attacked Kroll's independent report as "unbalanced", "selective" and "misleading".

Atlas Arteria fired back this morning, accusing its largest shareholder of launching a targeted, opportunistic attack on isolated aspects of the expert’s complex mathematical models.

At the time of reporting, Atlas Arteria’s share price was $5.02.